Keyphrases
Better Prognosis
100%
Breast Carcinoma
100%
Mammalian Target of Rapamycin (mTOR)
100%
Tumor
45%
Disease-free Survival
45%
Overall Survival
36%
Molecular Subtypes
18%
Subgroup Analysis
18%
Multivariable
18%
Size Grading
18%
Lymph Node Status
18%
Overexpression
9%
Minimal Change
9%
Contradictory Results
9%
Published Data
9%
Data Reporting
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Baseline Data
9%
Pathological Features
9%
Overall Survival Time
9%
PI3K-AKT-mTOR Pathway
9%
Medicine and Dentistry
Breast Carcinoma
100%
Mechanistic Target of Rapamycin
100%
Overall Survival
50%
Tumor
50%
Disease Free Survival
50%
Lymph Node
20%
Subgroup Analysis
20%
Retrospective Study
10%
Survival Time
10%
PI3K/AKT/mTOR Pathway
10%
Veterinary Science and Veterinary Medicine
Breast Carcinoma
100%
Diseases
71%
Tumor
71%
Lymph Node
28%
Biochemistry, Genetics and Molecular Biology
Mechanistic Target of Rapamycin
100%
Overall Survival
50%
Disease Free Survival
50%
Survival Time
10%
Retrospective Study
10%
PI3K/AKT/mTOR Pathway
10%
Immunology and Microbiology
Sirolimus
100%
Overall Survival
50%
Disease Free Survival
50%
Lymph Node
20%
Survival Time
10%